Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Carcinogenesis|February 8, 2013
Contrasting roles of dietary selenium and selenoproteins in chemically induced hepatocarcinogenesisMarina V Kasaikina, Anton A Turanov, Andrei Avanesov, et al.
Molecular Cell|August 6, 2013
MsrB1 and MICALs regulate actin assembly and macrophage function via reversible stereoselective methionine oxidationByung Cheon Lee, Zalán Péterfi, Fukun W Hoffmann, et al.
Nature Communications|June 19, 2023
Safety and immunogenicity of a phase 1/2 randomized clinical trial of a quadrivalent, mRNA-based seasonal influenza vaccine (mRNA-1010) in healthy adults: interim analysisIvan T Lee, Raffael Nachbagauer, David Ensz, et al.
Nature Communications|July 2, 2025
Immunogenicity and safety of mRNA-based seasonal influenza vaccines encoding hemagglutinin and neuraminidaseAmanda K Rudman Spergel, Ivan T Lee, Kindra Koslovsky, et al.
The Journal of Infectious Diseases|June 27, 2024
Safety and Immunogenicity of mRNA-1010, an Investigational Seasonal Influenza Vaccine, in Healthy Adults: Final Results From a Phase 1/2 Randomized TrialJintanat Ananworanich, Ivan T Lee, David Ensz, et al.
Vaccine|February 7, 2025
A phase 3 randomized safety and immunogenicity trial of mRNA-1010 seasonal influenza vaccine in adultsMieke Soens, Jintanat Ananworanich, Bryony Hicks, et al.
Human Vaccines & Immunotherapeutics|April 2, 2025
An mRNA-based seasonal influenza vaccine in adults: Results of two phase 3 randomized clinical trials and correlate of protection analysis of hemagglutination inhibition titersBoris Kandinov, Mieke Soens, Wenmei Huang, et al.
The Lancet. Infectious Diseases|September 8, 2024
Safety and immunogenicity of mRNA-based seasonal influenza vaccines formulated to include multiple A/H3N2 strains with or without the B/Yamagata strain in US adults aged 50-75 years: a phase 1/2, open-label, randomised trialDenise Hsu, Akila Jayaraman, Alicia Pucci, et al.
Human Vaccines & Immunotherapeutics|February 2, 2026
Phase 1/2 randomized, observer-blind clinical trial of a first-generation, mRNA-based vaccine against seasonal influenza and COVID-19 in healthy adultsAmanda K Rudman Spergel, Carole Henry, Raffael Nachbagauer, et al.
Bioanalysis|January 29, 2026
2025 White Paper on Recent Issues in Bioanalysis: Biomarkers Calibrators & Stability; Evaluation of NULISA; Neurofilament & Autoantibody Biomarker Assays; Removing IgM Interference; ELISpot & FluoroSpot Best Practices; Modular HD Cytometry; Single-cell Analysis Imaging Cytometry (PART 2A - Recommendations on Biomarkers Discovery, Development, Validation & Regulatory Approval, Ligand-Binding Assays (LBA) and Cell-Based Assays (CBA) PART 2B - Regulatory Agencies' Input on Biomarkers, IVD/CDx and Biomarker Assay Validation (BAV))Sarah Hersey, Kristina McGuire, Olga Kholmanskikh, et al.
Pageof 2